Mariner LLC Grows Holdings in Boston Scientific Co. (NYSE:BSX)

Mariner LLC grew its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 175,766 shares of the medical equipment provider's stock after purchasing an additional 11,030 shares during the period. Mariner LLC's holdings in Boston Scientific were worth $15,700,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of BSX. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider's stock valued at $11,869,805,000 after acquiring an additional 1,600,062 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Boston Scientific by 10.2% in the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock worth $3,230,293,000 after purchasing an additional 3,344,571 shares during the last quarter. Geode Capital Management LLC grew its position in Boston Scientific by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider's stock worth $2,729,371,000 after purchasing an additional 1,041,329 shares during the period. Norges Bank purchased a new stake in Boston Scientific during the 4th quarter valued at $1,762,522,000. Finally, Franklin Resources Inc. lifted its holdings in shares of Boston Scientific by 5.3% during the 4th quarter. Franklin Resources Inc. now owns 16,539,488 shares of the medical equipment provider's stock valued at $1,477,307,000 after buying an additional 832,386 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on BSX. Raymond James lifted their price objective on Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a report on Thursday, February 6th. Morgan Stanley upped their price target on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Needham & Company LLC upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $113.00 price objective on the stock in a research note on Wednesday, April 16th. UBS Group boosted their target price on shares of Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Finally, Piper Sandler increased their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. One research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $110.22.

Insider Transactions at Boston Scientific

In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of Boston Scientific stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the transaction, the executive vice president now directly owns 28,454 shares of the company's stock, valued at approximately $2,966,329.50. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares in the company, valued at $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 133,183 shares of company stock worth $13,948,476. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Price Performance

NYSE:BSX traded up $1.76 during trading hours on Tuesday, reaching $95.34. The stock had a trading volume of 1,487,196 shares, compared to its average volume of 7,827,010. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock has a market capitalization of $141.02 billion, a PE ratio of 76.22, a PEG ratio of 2.79 and a beta of 0.73. Boston Scientific Co. has a 52 week low of $67.80 and a 52 week high of $107.17. The company has a 50 day moving average price of $99.22 and a two-hundred day moving average price of $94.54.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, sell-side analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.